Topics

Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

06:55 EST 7 Nov 2019 | BioPharmaDive

With pivotal data for a Celgene CAR-T therapy set to soon be unveiled, the clock is ticking on a timeline that will determine whether Bristol-Myers pays billions more to the biotech's shareholders.

Original Article: Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

NEXT ARTICLE

More From BioPortfolio on "Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...